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http://www.molecularneurodegeneration.com/content/9/1/18RESEARCH ARTICLE Open AccessHippocampal neuronal cells that accumulate
α-synuclein fragments are more vulnerable to
Aβ oligomer toxicity via mGluR5 – implications
for dementia with Lewy bodies
Cassia R Overk1, Anna Cartier1, Gideon Shaked1, Edward Rockenstein1, Kiren Ubhi1, Brian Spencer1, Diana L Price2,
Christina Patrick1, Paula Desplats1 and Eliezer Masliah1,3*Abstract
Background: In dementia with Lewy bodies (DLB) abnormal interactions between α-synuclein (α-syn) and beta
amyloid (Aβ) result in selective degeneration of neurons in the neocortex, limbic system and striatum. However,
factors rendering these neurons selectively vulnerable have not been fully investigated. The metabotropic glutamate
receptor 5 (mGluR5) has been shown to be up regulated in DLB and might play a role as a mediator of the
neurotoxic effects of Aβ and α-syn in vulnerable neuronal populations. In this context, the main objective of the
present study was to investigate the role of mGluR5 as a mediator of the neurotoxic effects of α-syn and Aβ in the
hippocampus.
Results: We generated double transgenic mice over-expressing amyloid precursor protein (APP) and α-syn under
the mThy1 cassette and investigated the relationship between α-syn cleavage, Aβ, mGluR5 and neurodegeneration
in the hippocampus. We found that compared to the single tg mice, the α-syn/APP tg mice displayed greater
accumulation of α-syn and mGluR5 in the CA3 region of the hippocampus compared to the CA1 and other regions.
This was accompanied by loss of CA3 (but not CA1) neurons in the single and α-syn/APP tg mice and greater loss
of MAP 2 and synaptophysin in the CA3 in the α-syn/APP tg. mGluR5 gene transfer using a lentiviral vector into
the hippocampus CA1 region resulted in greater α-syn accumulation and neurodegeneration in the single and
α-syn/APP tg mice. In contrast, silencing mGluR5 with a lenti-shRNA protected neurons in the CA3 region of tg
mice. In vitro, greater toxicity was observed in primary hippocampal neuronal cultures treated with Aβ oligomers
and over-expressing α-syn; this effect was attenuated by down-regulating mGluR5 with an shRNA lentiviral vector.
In α-syn-expressing neuronal cells lines, Aβ oligomers promoted increased intracellular calcium levels, calpain
activation and α-syn cleavage resulting in caspase-3-dependent cell death. Treatment with pharmacological mGluR5
inhibitors such as 2-Methyl-6-(phenylethynyl)pyridine (MPEP) and 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP)
attenuated the toxic effects of Aβ in α-syn-expressing neuronal cells.
Conclusions: Together, these results support the possibility that vulnerability of hippocampal neurons to α-syn
and Aβ might be mediated via mGluR5. Moreover, therapeutical interventions targeting mGluR5 might have a role
in DLB.
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Alzheimer’s disease (AD) and Parkinson’s disease (PD)
are the leading causes of dementia and movement disor-
ders in the aging population. It is estimated that over 5
million people live with these devastating neurological
conditions in the US [1]. While in AD abnormal accu-
mulation of misfolded amyloid-β protein (Aβ) in the
neocortex and limbic system is responsible for the neu-
rodegenerative pathology [2,3], in PD accumulation and
propagation of α-synuclein (α-syn) has been centrally
implicated in this condition [4-6]. The pathogenesis of
AD and PD overlap in a heterogeneous group of condi-
tions denominated jointly as Lewy body disease (LBD)
[7,8], which includes dementia with Lewy bodies (DLB),
Parkinson’s disease with dementia (PDD) and idiopathic
PD (iPD). Direct and indirect interactions between α-syn
and Aβ play a role in the pathogenesis of LBD [9-13].
Specifically, Aβ promotes the oligomerization and toxic
conversion of α-syn [12,14]; Aβ worsens the deficits as-
sociated with α-syn accumulation [15,16]; Aβ and α-syn
co-localize in membrane and caveolar fractions [13]; and
Aβ stabilizes α-syn multimers that might form hetero-
multimers in the membrane [13].
In DLB, neuronal populations degenerate in the neo-
cortex, CA3 region of the hippocampus, and mid-spiny
neurons in the striatum [17,18] Among the cell-
autonomous factors that might render neurons vulner-
able in DLB to the combined effects of Aβ and α-syn, it
has been proposed that the expression profile of mGluRs
might be a determinant for the degeneration of the hip-
pocampal formation and neurons in DLB [19]. Consider-
able interest in mGluR5 [20] has developed in the last
few years due to: 1) its potential involvement in AD [21]
and PD [22,23], 2) the role of this receptor in learning
and memory [24,25], 3) mGluR5 is abundantly expressed
in the neocortex, limbic system and caudoputamen
[26]—brain regions selectively affected in AD and PD,
and 4) selective inhibitors of mGluR5, 2-methyl-6-
(phenylethynyl)pyridine (MPEP) and 3-((2-Methyl-4-
thiazolyl)ethynyl)pyridine (MTEP), are currently being
considered as potential therapies for neurodegenera-
tive disorders [23].
mGluR5 is more abundant in the hippocampal pyram-
idal neurons, the nucleus accumbens, and striatum of the
basal ganglia and granular cells in the olfactory bulb (OB)
[27,28], and is expressed at low levels in the cerebellum
[26]. In AD and DLB the mGluR/phospholipase C (PLC)
signaling pathways are impaired [29]. Moreover, Aβ dysre-
gulates the PKC-dependent functions of mGluRs in cor-
tical neurons [30] and the levels of mGluR5 are abnormal
in AD patients, and are up regulated in the Down’s syn-
drome brains [31].
Remarkably, we have shown that in DLB and PD pa-
tients and α-syn transgenic (tg) mice there is increasedexpression of mGluR5 in the hippocampus and striatum
[19]. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) model of dopaminergic damage, activation of
mGluR5 contributes to the neurodegenerative process
[32] and mGluR5 blockers, such as MPEP, protect neu-
rons from MPTP and 6-OH dopamine (DOPA) chal-
lenge [33-35].
Taken together, these studies suggest that mGluR5
might play a role as a mediator of the neurotoxic effects
of Aβ and α-syn in AD and PD. In this context, the main
objective of the present study was to investigate the role
of mGluR5 as a mediator of the neurotoxic effects of α-
syn and Aβ in the hippocampus. We found that degen-
eration of the CA3 region of the hippocampus in α-syn/
APP double tg mice was associated with increased accu-
mulation of α-syn and increased expression of mGluR5.
Down regulation of mGluR5 was protective while ec-
topic overexpression of mGluR5 in the CA1 resulted in
neurodegeneration. In α-syn expressing neuronal cells
lines, Aβ oligomers promoted increased intracellular cal-
cium levels, calpain activation and α-syn cleavage, result-
ing in caspase-3 dependent cell death. Together, these
results support the possibility that vulnerability of hippo-
campal neurons to α-syn and Aβ might be mediated via
mGluR5.
Results
Characterization and comparison of mRNA and protein
expression in transgenic mouse lines expressing APP,
α-syn and α-syn/APP
In order to understand the role of α-syn and Aβ in
mediating neurodegeneration in the hippocampus via
mGluR5, we generated α-syn/APP double tg mice by
crossing mThy1-α-syn (Line 61) and mThy-1 APP
(Line 41) (Figure 1A). We chose to cross these two spe-
cific tg lines to ensure co-expression of APP and α-syn in
the same neuronal populations, at comparable levels, and
because each individual line has shown robust pathology
in vulnerable areas relevant to AD and PD [36,37]. Quan-
titative PCR (qPCR) analysis of mRNA isolated from
brain tissue demonstrated the presence of comparable
levels of hAPP mRNA in the APP and α-syn/APP tg
mice (Figure 1B). Analysis of the same brain tissues for
α-syn mRNA revealed comparable levels of hα-syn in both
α-syn single tg and the α-syn/APP double tg mouse lines
(Figure 1B). Double labeling and laser scanning confocal
microscopy studies confirmed that in the α-syn/APP tg
mice the same neuronal populations co-express human
amyloid precursor protein (hAPP) and human α-syn
(hα-syn) (Figure 1C). Consistent with the mRNA and
immunohistochemical analysis, Western blot experi-
ments also confirmed the presence of the native α-syn
band at approximately 14 kDa in the non-tg and tg mice
lines. In line with previous studies [9,12], the α-syn/APP
Figure 1 Generation and characterization of tg mice expressing α-syn, APP or α-syn/APP under the mThy1 promoter. A. Schematic
representation of the α-syn and APP single tg mice. B. Levels of hAPP mRNA and hα-syn mRNA expressed as a ratio to the housekeeping gene
GAPDH in non-tg APP, α-syn, and α-syn/APP tg mice. Mice express comparable levels of hAPP mRNA in the APP and α-syn/APP tg mice, as well
as similar levels of α-syn mRNA in the α-syn and α-syn/APP tg mice. C. Laser scanning confocal microscopy studies confirmed that in the
α-syn/APP tg mice the same neuronal populations co-express human amyloid precursor protein (hAPP) and human α-syn (hα-syn); scale
bar = 10 μm. D Representative Western blot and E analysis showed the presence of native α-syn (14 kDa) in the membrane fraction all
mice with the most enhanced accumulation of α-syn (monomeric and oligomers) occurring in α-syn/APP mice when compared to the α-syn tg
mice (p-value < 0.05). F. Representative Western blot and G analysis of hAPP revealed that full length APP and Aβ levels were comparable between
APP tg and α-syn/APP tg mice and APP. For analysis, N = 6 mice (3–4 months old) from each line were utilized. * = p-value < 0.05 by one-way ANOVA
with a Tukey-Kramer post hoc analysis.
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meric and oligomers) when compared to the α-syn tg
mice (p-value < 0.05; Figure 1D and E). Western blot
evaluation of APP revealed that full length (FL-) APP and
Aβ levels were comparable between APP tg and α-syn/
APP double tg mice (Figure 1F and G).
Full-length α-syn and mGluR5 are increased in the CA3
pyramidal layer of the hippocampus in α-syn/APP mice
compared to α-syn tg mice
To investigate the effects of the co-expression of α-syn
and APP on mGluR5 levels in the hippocampus, im-
munocytochemical and image analysis was performed.
We focused on the hippocampus because in previous
studies we showed that the levels of mGluR5 were up
regulated in the CA3 in a different single tg α-syn mouseline [19]. As expected, utilizing an antibody against total
full-length α-syn that revealed the endogenous punctate
pattern in the neuropil of the CA1 and CA3 regions in the
non-tg and APP single tg mice (Figure 2A). In contrast, in
the α-syn tg and α-syn/APP double tg mice α-syn was
present in the neuronal cell bodies and had a significantly
enhanced punctate pattern in the neuropil (Figure 2). In
the CA3 there was a statistically significant increase in α-
syn in the α-syn/APP double tg line compared with the α-
syn single tg line (p-value < 0.05; Figure 2A and B); while
in the CA1, the increase in α-syn in α-syn tg line was
equivalent to the increase in the a-syn/APP double tg line,
which were both significantly increased compared to non-
tg mice (p-value < 0.05; Figure 2A and C).
Immunocytochemical analysis of mGluR5 revealed en-
dogenous punctate pattern in the neuropil of non-tg mice
Figure 2 Comparison of the patterns of full-length α-synuclein in the hippocampus of APP, α-syn, and α-syn/APP tg mice.
Vibratome sections were immunostained with rabbit polyclonal antibody against full-length total α-syn (Millipore) A. Low- and
high-magnification photomicrographs of the CA3 and CA1 regions of the hippocampus from non-tg, APP, α-syn, and α-syn/APP tg
mice immunoreacted with anti-syn. Endogenous α-syn was observed in a punctate pattern in the neuropil of CA1 and CA3 in the
non-tg and APP tg mice which was significantly enhanced in the α-syn and α-syn/APP tg mice. Moreover, α-syn and α-syn/APP tg mice
also had α-syn in the neuronal cell bodies. B. Corrected optical densitometry analysis of the hippocampal CA3 region revealed that
α-syn was significantly enhanced in both the α-syn and α-syn/APP tg mice compared to non-tg mice α-syn, and α-syn was significantly
increased in the α-syn/APP double tg line compared with the α-syn single tg line. C. In the CA1, the increase in α-syn in α-syn tg line
was equivalent to the increase in the α-syn/APP double tg line, which were both significantly increased compared to non-tg mice. Scale
bars = 10 and 50 μm for the low and high magnifications, respectively. * = p-value < 0.05 by one-way ANOVA and Dunnett’s post hoc
analysis compared to non-tg mice. # = p-value < 0.05 by one-way ANOVA and Tukey-Kramer post hoc analysis when, compared to
α-syn/APP tg mice. For each analysis, N = 6 (3–4 months old) mice from each line were utilized.
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single tg mice, mGluR5 was significantly increased in the
cell bodies, as well as in the punctate pattern of the neuro-
pil in the CA3 compared to non-tg mice (p-value < 0.05;
Figure 3A and B). In α-syn/APP double tg mice, mGluR5
levels were statistically enhanced (p-value < 0.05) com-
pared to α-syn single tg mice in the CA3, with mGluR5
increased in both the neuronal cell bodies, as well as in
the neuropil (Figure 3A and B). While mGluR5 levels were
increased in the CA3 across all tg lines, there was no in-
crease in the CA1 compared to non-tg mice (Figure 3A
and C), suggesting that the CA3 is selectively vulnerable
to alterations in mGluR5 levels. Since there was an in-
creased expression of mGluR5 in the CA3 pyramidal cell
layer in α-syn/APP double tg mice, which paralleled the
increase in FL-α-syn expression in the CA3 pyramidal cell
layer of α-syn/APP mice compared to α-syn mice, sections
were double-labeled for α-syn and mGluR5. Confocal mi-
croscopy of the CA3 pyramidal cell layer of the hippocam-
pus confirmed that mGluR5 was increased in the presence
of, and co-localized with, α-syn in both the α-syn tg and
α-syn/APP double tg mouse lines compared to APP tg
and non-tg mice (Figure 3D).Hippocampal CA3 but not CA1 pyramidal cells selectively
vulnerable in APP, α-syn, and α-syn/APP tg mice
Based on the observation that mGluR5 and FL-α-syn are
increased in the CA3 but not CA1, stereological analysis
was performed to determine if the CA3 was selectively
vulnerable to neurodegeneration in the APP, α-syn and
α-syn/APP tg mouse lines (Figure 4). The number of
NeuN-positive cells in the CA3 was significantly de-
creased by approximately 50% across all tg mouse lines
(p-value < 0.05; Figure 4B) but remained unaffected in
the CA1 pyramidal cell layer (Figure 4C). To further in-
vestigate the selective neurodegeneration in the hippocam-
pal CA3 pyramidal layer, immunocytochemical analysis
was performed with other markers including MAP 2
(dendritic marker), synaptophysin (pre-synaptic terminal
marker), GFAP (astroglial cells), and Iba-1 (microglial
cells). In the CA3 region of the non-tg mice, MAP 2-
immunoreactivity (−ir) was found in the neuronal cell
bodies and dendrites using confocal microscopy. In con-
trast, APP, α-syn and α-syn/APP tg mice displayed a re-
duction on MAP 2 immunolabeling in the CA3 region
(p-value < 0.05; Figure 5A and B). The most dramatic
loss in MAP 2-ir was in the α-syn/APP double tg mice,
Figure 4 Decreased number of hippocampal CA3 but not CA1 pyramidal cells in APP, α-syn, and α-syn/APP tg mice. A. Representative
low- and high-photomicrographs of the hippocampal CA3 and CA1 regions of sections immunoreacted with NeuN. B. Stereological assessment
of every 12th section revealed a significant decrease in the number of neurons in the CA3. C. However, the number of neurons in the CA1 region
was unaffected across all tg mouse line. Statistical analysis was conducted using one-way ANOVA post hoc Dunnett’s compared to non-tg mice;
* p-value < 0.05. For analysis N = 3 (3–4 mos old) from each line were utilized.
Figure 3 Immunocytochemical analysis of mGluR5 in the hippocampus of APP, α-syn, and α-syn/APP tg mice. Vibratome sections were
immunostained with an antibody against mGluR5. A. Low- and high-magnification photomicrographs of the CA3 and CA1 regions of the
hippocampus from non-tg, APP, α-syn, and α-syn/APP tg mice immunoreacted with anti-mGluR5. Endogenous mGluR5 was observed in a
punctate pattern in the neuropil of CA1 and CA3 in the non-tg mice. In the CA3, but not the CA1 the APP, α-syn, and α-syn/APP tg mice had
mGluR5 in the neuronal cell bodies, and the punctate staining in the neuropil was significantly enhanced. B. Corrected optical densitometry
analysis of the hippocampal CA3 region revealed that mGluR5 was significantly enhanced across all tg mice compared to non-tg mice α-syn, and
mGluR5 was significantly increased in the α-syn/APP double tg line compared with the α-syn single tg line. C. In the CA1, there was no significant
difference in the amount of mGluR5 in any of the tg line compared to the non-tg line. D. Confocal imaging of CA3 hippocampus double-labeled
with α-syn and mGLuR5 confirmed the presence and increase in mGluR5 with α-syn in both the α-syn and α-syn/APP tg mice. Scale bars = 10
and 50 μm for the low and high magnifications, respectively. * = p-value < 0.05 by one-way ANOVA and Dunnett’s post hoc analysis compared to
non-tg mice. # = p-value < 0.05 by one-way ANOVA and Tukey-Kramer post hoc analysis when, compared to α-syn/APP tg mice. For each analysis,
N = 6 (3–4 months old) mice from each line were utilized.
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Figure 5 Hippocampal CA3 brain region selectively vulnerable in APP, α-syn, and α-syn/APP tg mice. Immunocytochemical analysis was
performed in the hippocampal CA3 pyramidal layer. A. Representative confocal, MAP 2- (dendritic marker) and synaptophysin- (pre-synaptic
terminal marker), and photomicrographs of GFAP- (astroglial cells) and Iba-1- (microglial cells) ir. MAP 2-ir found in neuronal cell bodies and
dendrites, was reduced in APP, α-syn and α-syn/APP tg mice. Synaptophysin was abundant in punctate staining in non-tg pre-synaptic nerve
terminals and reduced in α-syn and α-syn/APP tg mice. GFAP-positive astroglial cells had small cell bodies with short processes in the non-tg
mice, while APP, α-syn, and α-syn/APP tg mice had GFAP-positive astroglia with enlarged cell bodies and extended processes. Non-tg mice
displayed strongly immunoreactive discrete Iba-1-immunoreactive microglia, which increased in APP, α-syn and α-syn/APP tg mice B. The percent
area of MAP 2-ir neuropil was significantly decreased in all tg lines compared to non-tg mice, with the greatest loss in the α-syn/APP double tg
mice. C. The percent of synaptophysin-ir neuropil area revealed a significant reduction in α-syn tg mice and further reduction in α-syn/APP tg
mice. D. Optical density image analysis revealed a significant increase in GFAP-ir in the APP and α-syn tg mice, which was greatest in α-syn/APP
double tg mice compared to non-tg mice. E. Image analysis confirmed a significant increase in the number of Iba-1-positive cells in APP and
α-syn single tg mice, which was greatest in α-syn/APP double tg mice. * = p-value < 0.05 and ** = p-value < 0.01 by one-way ANOVA and
Dunnett’s post hoc analysis compared to non-tg mice. # = p-value < 0.05 by one-way ANOVA and Tukey-Kramer post hoc analysis when
compared to α-syn/APP tg mice. For each analysis, N = 6 (3–4 months old) mice from each line were utilized.
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neuropil, both compared to non-tg mice (p-value < 0.01),
as well as compared to α-syn single tg mice (p-value <
0.05; Figure 5A and B). Confocal microscopy and image
analysis of synaptophysin in CA3 revealed abundant punc-
tate staining in the pre-synaptic nerve terminals of non-tg
mice (Figure 5A). While there was not much difference
between in synaptophysin levels in non-tg and APP mice,
the area of the neuropil that was synaptophysin-positive
was significantly reduced in α-syn tg mice (p-value < 0.05)
and even further reduced in the α-syn/APP tg mouse line
(p-value < 0.01) in the CA3 of the hippocampus (Figure 5A
and C).
While the non-tg mice had GFAP-positive astroglial
cells within small cell bodies and short processes, APP,
α-syn, and α-syn/APP tg mice had GFAP-positive astro-
glia with enlarged cell bodies and extended processes
(Figure 5A). Optical density image analysis revealed a sig-
nificant increase in GFAP-ir in the APP (p-value < 0.05)
and α-syn (p-value < 0.05), with the greatest increase in
α-syn/APP double tg mice (p-value < 0.01) compared
to non-tg mice in the CA3 region (Figure 5A and D).
Non-tg mice displayed the presence of discrete Iba-1-immunoreactive microglia (Figure 5A). In the tg lines,
morphological analysis revealed that APP, α-syn and α-
syn/APP mice contained Iba-1-positive processes that
were strongly Immunoreactive with increased staining of
microglia processes. Image analysis confirmed a signifi-
cant increase in the number of Iba-1-positive cells in
APP (p-value < 0.05) and α-syn (p-value < 0.05) single tg
mice, which was most increased in α-syn/APP double tg
mice (p-value < 0.05) in the CA3 region (Figure 5E).
Lentivirus mediated delivery of mGluR5 in vivo in the CA1
region is associated with increased vulnerability in a
previously unaffected region
To investigate if increasing the levels of mGluR5 results
in enhanced vulnerability of un-affected regions in the
hippocampus, lentiviruses expressing either a control
vector or mGluR5 was injected into the CA1 region of
non-tg and tg mice (Figure 6A). As expected, following
the injection of the lentivirus (LV) control, the levels and
patterns of mGluR5 immunostaining in the CA1 where
comparable among the non-tg and tg lines. Levels of α-
syn were higher in the α-syn and α-syn/APP and compar-
able in the non-tg and APP tg mice (Figure 6B and C).
Figure 6 Creating mGLuR5-mediated vulnerability in the CA1 region via lentivirus delivery in vivo. A. Schematic representation of
lentivirus expressing either control vector or mGLuR5 that was injected unilaterally in the CA1 of the hippocampus. B. Representative
photomicrographs and C image analysis of sections from mice injected with LV-control and immunoreacted with mGluR5, α-syn and MAP 2.
Injecting LV-control had no effect on either non-tg or tg mice and was comparable to the initial characterization of these mice in which levels of
mGLuR5 remained the same, α-syn increased in α-syn and α-syn/APP tg mice, and MAP 2-ir was unaffected. D. Representative photomicrographs
and E. image analysis revealed that injection of the LV-mGluR5 resulted in a significant increase in mGluR5 in the neuronal cell bodies and
dendrites in the CA1 of the hippocampus in the non-tg and tg lines. While α-syn remained unaffected by LV-mGluR5 with α-syn increased in
α-syn and α-syn/APP tg mice, MAP 2-ir was significantly reduced in dendrites in the CA1 region. * = p-value < 0.05 and ** = p-value < 0.01 by
one-way ANOVA and Dunnett’s post hoc analysis compared to non-tg mice. For each analysis, N = 6 (3–4 months old) mice from each line
were utilized.
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the CA1 was similar among non-tg and tg lines (Figure 6B
and C). In contrast, injection of the LV-mGluR5 resulted
in a significant increase in mGluR5 in the neuronal cell
bodies and dendrites in the CA1 of the hippocampus in
the non-tg and tg lines (Figure 6D). There was a signifi-
cant accumulation of α-syn in the CA1 region in the α-
syn and α-syn/APP tg mice compared to non-tg and
APP tg mice (Figure 6D and E). Moreover the accumula-
tion of α-syn in the tg lines was greater in mice injected
with LV-mGluR5 when compared to mice injected
with the LV-control in the CA1 region. Confocal ana-
lysis of MAP 2 in the CA1 region showed that com-
pared to the non-tg mice, APP and α-syn and α-syn/
APP tg mice that were injected with LV-mGluR5 re-
sulted in significant reduction of dendrites in the CA1
region (Figure 6D and E). Taken together, these results
supports the possibility that increased expression of
mGluR5 in the CA3 plays a role in the vulnerability
of this region in tg mice and that ectopic over-expression
of mGluR5 in the CA1 results in neurodegeneration.
Down-regulation of mGluR5 with a lentivirus sh-RNA
protects hippocampal neuronal cells from the neurotoxic
effects of Aβ and α-syn
Next we wanted to ascertain if down-regulating mGluR5
in the hippocampus would be protective in models of Aβand α-syn toxicity. To investigate if reducing the levels of
mGluR5 results in decreased toxicity in the hippocam-
pus, lentiviruses expressing either a control vector or
sh-mGluR5 was injected into the CA3 region of non-tg
and tg mice (Figure 7A). In the LV-control group, the
levels of mGluR5 were higher in the CA3 in the α-syn and
α-syn/APP and comparable in the non-tg and APP tg
mice (Figure 7B and C). The percent area covered by
MAP 2 dendrites in the CA3 was significantly reduced in
the APP, α-syn and α-syn/APP compared to non-tg and tg
lines (Figure 7B and C). In contrast, injection of the LV-sh
mGluR5 resulted in a significant decrease in mGluR5 in
the neuronal cell bodies and dendrites in the CA3 of the
hippocampus in the non-tg and tg lines (Figure 7D). There
was a significant accumulation of α-syn in the CA3 region
in the α-syn and α-syn/APP tg mice compared to non-tg
and APP tg mice (Figure 7D and E). Confocal analysis
of MAP 2 in the CA3 region showed that% area of the
neuropil was comparable between the non-tg mice and
the APP and α-syn and α-syn/APP tg (Figure 7D and E).
Taken together, these results support the notion that re-
duced expression of mGluR5 in the CA3 is protective.
To confirm the effects in an independent system in vitro,
primary hippocampal neuronal cells were infected with an
LV-sh-mGluR5 or LV-sh-Luc (control targeting luciferase)
in combination with Aβ and α-syn. First we evaluated the
expression of mGluR5; as expected, cells injected with
Figure 7 Down-regulation of mGLuR5 in the CA3 region via shRNA lentivirus delivery is protective. A. Schematic representation of
lentivirus expressing either control vector or sh mGLuR5 that was injected unilaterally in the CA3 of the hippocampus. B. Representative
photomicrographs and C image analysis of sections from mice injected with LV-control and immunoreacted with mGluR5, α-syn and MAP 2.
Injecting LV-control had no effect on either non-tg or tg mice and was comparable to the initial characterization of these mice in which levels of
mGLuR5, α-syn, and MAP 2-ir. D. Representative photomicrographs and E. image analysis revealed that injection of the LV-sh mGluR5 resulted in
a significant reduction in mGluR5 in the neuronal cell bodies and dendrites in the CA3 of the hippocampus in the non-tg and tg lines. While
α-syn remained unaffected by LV-sh mGluR5 with α-syn increased in α-syn and α-syn/APP tg mice, levels of MAP 2-ir were improved in the CA3
region. * = p-value < 0.05 and ** = p-value < 0.01 by one-way ANOVA and Dunnett’s post hoc analysis compared to non-tg mice. # = p-value < 0.05 by
one-way ANOVA and Tukey-Kramer post hoc analysis when compared to α-syn/APP tg mice. For each analysis, N = 6 (3–4 months old) mice from each
line were utilized.
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by immunocytochemistry (Figure 8A) and Western blot
(Figure 8B). In contrast, cells infected with the LV-sh-
mGluR5 displayed a significant 80% reduction in mGluR5
expression (Figure 8B). Next neuronal cells were co-
infected with a LV-control or LV-α-syn and treated with
vehicle or Aβ oligomers and analyzed by confocal micros-
copy for neuritic processes and α-syn levels (Figure 8C).
Compared to the control, neuronal cells infected with
LV-α-syn displayed 35-40% reduction in neurite length
(Figure 8C and D), likewise neuronal cells infected with
LV-control and challenged with Aβ oligomers alone re-
sulted in 40-50% loss in neurite length that was worsened
in cells infected with LV-α-syn (Figure 8C and D). Com-
pared to control experiments using LV-sh-Luc, down
modulation of mGluR5 with LV-sh-mGluR5 rescued the
neuritic phenotype in both neuronal cells infected with
LV-α-syn alone, treated with Aβ oligomers alone or in
combination (Figure 8C and D). As expected neuronal
cells infected with LV-α-syn expressed higher levels of α-
syn (Figure 7C and E). Compared to vehicle treated cells,
levels of α-syn where higher in infected cells treated with
Aβ oligomers (Figure 8C and E). Down modulation of
mGluR5 with LV-sh-mGluR5 had no effects on levels α-
syn (Figure 8E). By LDH assay, compared to the control,
neuronal cells infected with LV-control and challenged
with Aβ oligomers alone resulted in greater neuronal cell
death that was worsened in cells infected with LV-α-syn(Figure 8F). Compared to control experiments using
LV-sh-Luc, down modulation of mGluR5 with LV-sh-
mGluR5 protected neurons from the toxic effects of
Aβ oligomers and -α-syn (Figure 8F).
Aβ and α-syn promotes cell death and abnormal calcium
flux via mGluR5 in a neuronal cell line
Since previous have shown that mGluR5 might be in-
volved in mediating the toxic effects of Aβ [30,38-42], and
mGluR5 deficient mice or mice treated with mGluR5 in-
hibitors are protected from MPTP-induced toxicity in
models of parkinsonism [25,34,43], we tested the role of
mGluR5 in mediating toxicity in our system. For this pur-
pose, the co-pathogenic mechanisms of Aβ and α-syn tox-
icity were investigated in the B103 rat neuroblastoma cells
that were infected with LV-α-syn and treated with Aβ olig-
omers (10 μM) for 24 h. Levels of mGluR5 were analyzed,
both by immunocytochemistry (Figure 9A and B) and WB
(Figure 9C). The LV-control infected cells expressed low
levels of mGluR5; in contrast, neuronal cells infected with
LV-α-syn and challenged with control media or Aβ oligo-
mers displayed an increase in mGluR5 levels over control
(Figure 9C).
Since activation of mGluR5 results in increased intra-
cellular calcium [20] and both α-syn [44] and Aβ [45,46]
raise this ion, intracellular calcium was measured as pre-
viously described using fluorescence-based assay, FLIPR
(Molecular Devices). In the LV-control infected cells,
Figure 8 Blocking mGLuR5-mediated neuronal vulnerability to Aβ and α-syn in the hippocampal neurons via lentivirus shRNA delivery
in vitro. A. Confocal imaging and B Western blot of primary neuronal hippocampal cells, which endogenously express mGluR5. LV-sh-luciferase
(control LV-sh) had no effect on the expression of mGluR5, while LV-sh-mGluR5 effectively reduced endogenous mGluR5 expression by 80%.
C. Confocal microscopy of neuronal cells co-infected with LV-control or LV-α-syn in the presence of either LV-sh-Luc or LV-sh-mGluR5 and treated with
vehicle or Aβ oligomers and double labeled with antibodies against α-syn and MAP 2. D. Image analysis revealed that neurite distance (MAP 2) was
reduced 35-40% in neuronal cells infected with LV-α-syn, and when this system was challenged with Aβ oligomers, neurite length was further reduced
to 40-50% of control. While LV-sh-Luc had no effect on neurite length in either the presence or absence of Aβ oligomers, down modulation of mGluR5
using LV-sh-mGluR5 rescued neurite length in neuronal cells treated with LV-α-syn, as well as with the combined toxicity of LV-α-syn and Aβ oligomers.
E. Image analysis of α-syn revealed that neuronal cells infected with LV-α-syn expressed higher levels of α-syn compared to untreated cells, and that
Aβ oligomers further increased this expression compared with cells only treated with LV-α-syn. Down modulation of mGluR5 with LV-sh-mGluR5 had
no effect on α-syn levels. F. Neuronal survival by LDH, showing that down-modulation of mGluR5 is protective form the toxic effects of Aβ oligomers
and α-syn. * = p-value < 0.05 by one-way ANOVA and Dunnett’s post hoc analysis compared to vehicle-treated uninfected neurons. # = p < 0.05 by
one-way ANOVA and Tukey-Kramer post hoc analysis when compared to LV-α-syn + Aβ oligomers.
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crease in intracellular calcium compared to control
cells (Figure 9D). Treatment of LV-α-syn cells with the
mGluR5 agonist- DHPG (1 μM, 24 h) showed similar re-
sults to the Aβ-treated group (Figure 9D). In the LV-α-syn
infected cells, Aβ challenge resulted in approximate three-
fold increase in intracellular calcium compared to control
cells (Figure 9D). The combined effects of α-syn and
Aβ on intracellular calcium levels were attenuated upon
pre-treatment with the mGluR5 antagonists – MPEP
(200 μM) and MTEP (20 μM) (Figure 9D). Using the lac-
tate dehydrogenase (LDH) toxicity assay we found that
while LV- α-syn infected cells displayed low toxicity, Aβ
enhanced LV-α-syn toxicity to approximately three-times
basal levels (p < 0.001) comparable to the toxicity levels of
the mGluR5 agonist -DHPG (Figure 9E). The combinedneurotoxic effects of LV-α-syn and Aβ were attenuated
upon pre-treatment with the mGluR5 antagonists, MPEP
and MTEP (Figure 9E). Together, these results support
the possibility that α-syn and Aβ promote toxicity via in-
crease intracellular calcium flux than in turn could acti-
vate proteases.
Aβ promotes calpain mediated α-syn fragmentation and
caspase-3 dependent cell death in α-syn-expressing
neuronal cells
Since previous studies suggest that intracellular calcium
results in calpain-I activation and C-terminus cleavage
of α-syn (Figure 10A), LV-α-syn infected B103 neuronal
cells were treated with Aβ and analyzed by WB. Remark-
ably, in cells treated with Aβ (10 μM, 24 h), the levels of
FL-α-syn in the cytosolic fraction (soluble) were
Figure 9 α-Synuclein and Aβ effect mGluR5 to promote toxicity via increase intracellular calcium flux. The co-pathogenic mechanisms of
Aβ and α-syn toxicity were investigated in the B103 rat neuroblastoma cells infected with LV-α-syn and treated with Aβ oligomers.
A. Immunocytochemistry, B image analysis and C. Western blot analysis of the levels of mGluR5 in B103 cells revealed the lowest levels
in vehicle treated cells. mGluR5 was significantly increased in cells treated with Aβ or LV-α-syn alone; and mGluR5 levels were the highest
in cells treated with both Aβ and LV-α-syn. Aβ increased levels of α-syn in cells where both were present. D. Intracellular calcium levels,
as measured using the fluorescence-based FLIPR assay, revealed that Aβ treatment resulted in a two-fold increase in intracellular calcium
compared to control cells. While LV-α-syn had no effect on its own, in combination with Aβ there was a three-fold increase in intracellular calcium,
which was similar to the effect of treating cells with the mGluR5 agonist DHPG. Pretreating B103 cells with mGluR5 antagonists MPEP and MTEP prior
to Aβ and LV-α-syn exposure attenuated the intracellular calcium increase. E. In the lactate dehydrogenase (LDH) toxicity assay, B103 cells
were unaffected by LV-α-syn; however, the percent cell death dramatically increased when LV-α-syn was combined with Aβ oligomers.
The mGluR5 agonist DHPG caused a similar level of cell death, while pretreatment with the mGluR5 antagonists MPEP and MTEP attenuated the
neurotoxic effects and reduced cell death to levels similar to LV-α-syn alone. * = p-value < 0.05 by one-way ANOVA and Dunnett’s post hoc analysis
compared to vehicle-treated control.
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brane fraction (insoluble) two immunoreactive bands were
observed. An antibody specific for the C-terminal (CT)
fragment of α-syn [47] confirmed that the shorter frag-
ment generated was a CT-α-syn (Figure 10B). By con-
focal microscopy, LV-α-syn infected B103 cells treated
with Aβ displayed increased CT-α-syn-ir (Figure 10C and
D; p-value < 0.05). This suggests that proteolytic enzymes
in the presence of Aβ might cleaved α-syn. Previous stud-
ies suggest that calpain-I (Figure 10A) might be involved
in this process [48-51]. Consistent with this possibility,
analysis of β-spectrin degradation by immunoblot showed
that in LV-α-syn infected B103 cells treated with Aβ
had an increased generation of β-spectrin fragmentsat 145/150 kDa and at 120 kDa (Figure 10E). FL β-spectrin
is a 240 kDa protein, while a 145/150 kDa doublet is in-
dicative of calpain cleavage, and the 120 kDa frag-
ment is indicative of caspase-3 cleavage. The calpain-I
mediated generation of CT α-syn in Aβ- treated cells
was associated with activation of caspase-3 as reveled by
immunocytochemical analysis (Figure 9F) and increased
cell death by LDH (Figure 10G). Consistent with these
findings, pre-treatment with calpain-I (calpeptin IV) or
caspase-3 (z-DEVD-FMK) inhibitors significantly reduced
cell death in LV-α-syn infected neuronal cells treated
with Aβ (Figure 10G). Moreover, after 24 h incuba-
tion, co-IP analysis showed that α-syn interacts with
caspase-3 (Figure 10H).
Figure 10 Aβ promotes calpain mediated α-syn fragmentation and caspase-3 dependent cell death in α-syn-expressing neuronal cells.
A. Diagrammatic representation of calpain-mediated α-syn cleavage resulting in C-terminus truncation of α-syn. B. Representative Western blot
showing increased levels in both FL-α-syn (14 kDa) in the cytosolic (single band) and membrane (double band) fractions, as wells as an increase
in C-terminus cleavage of α-syn (12 kDa) when cells were pre-treated with Aβ. C. Representative confocal microscopy and D image analysis of
B103 neuroblastoma cells treated with combinations of LV-α-syn and/or Aβ oligomers revealed increased CT-α-syn-ir (* p < 0.05; one-way ANOVA
and Dunnett’s post hoc analysis compared to LV-α-syn treated with vehicle). E. Increased β-spectrin degradation by calpain and caspase-3, in the
presence of LV-α-syn and Aβ. F. Caspase-3 activity was increased in cells treated with Aβ alone and combined with LV-α-syn. * p < 0.05; one-way
ANOVA and Dunnett’s post hoc analysis compared to uninfected, vehicle-treated control. G. Calpain and caspase inhibitors rescued cell death
induced by combined toxicity of Aβ and LV-α-syn. H. Co-ip of α-syn and caspase-3 in the presence of Aβ.
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α-syn/APP tg mice
To verify the effects on α-syn truncation in an in vivo
model, Aβ and caspase-3 activation was determined using
immunocytochemical and western blot analysis was per-
formed. By confocal microscopy, APP and α-syn tg mice
displayed a moderate increase in activated caspase-3-ir
in the CA3 region of the hippocampus while the bigenic
α-syn/APP mice showed an even greater increase com-
pared to non-tg controls, (Figure 11A and B). Likewise,
immunocytochemical analysis with an antibody against
CT-α-syn showed a 0.5 to 1 fold increase in the sin-
gle tg mice, while in the α-syn/APP tg mice displayed
a 2.5 fold increase in the accumulation of CT- α-syn
in the CA3 of the hippocampus (Figure 11C and D).
By Western blot analysis using an antibody against CT-
α-syn, detected a 12 kDa fragment at low levels in
the single tg mice, while higher levels were detected
in the α-syn/APP tg mice (Figure 11E and F). Moreover
and consistent with the immunocytochemical analysis,
levels of mGluR5 were higher in the α-syn and in the
α-syn/APP tg mice compared to non-tg control mice
(Figure 11E and F).
Taken together these results are in agreement with the
in vitro experiments and suggest that vulnerability of hip-
pocampal neurons to α-syn and Aβ might be mediated viamGluR5 via calpain and caspase-3 activation resulting in
CT-truncation of α-syn.
Discussion
The present study showed that in single tg as well as in α-
syn/APP tg mice the vulnerability of the CA3 region of
the hippocampus to the combined effects of α-syn and Aβ
are associated with increased mGluR5 and CT-α-syn ac-
cumulation. Moreover, while mGluR5 gene transfer into
the CA1 region (that otherwise was preserved) re-
sulted in neurodegeneration, silencing mGluR5 in the
CA3 was protective in the single and α-syn/APP tg
mice. In agreement with the in vivo studies, Aβ toxicity
was enhanced in α-syn expressing neuronal cell cultures
and the effect was attenuated by down-regulating mGluR5
with an shRNA lentiviral vector or pharmacologically
with MPEP/MTEP. In α-syn expressing neuronal cells, Aβ
oligomers promoted increased intracellular calcium levels,
calpain-I activation and α-syn cleavage resulting in caspase-
3 dependent cell death.
These findings are consistent with our previous study
showing that mGluR5 is elevated in the hippocampus of
DLB patients, as well as in α-syn tg mice [19]. While in
the previous study we analyzed PDGF-α-syn (line D) mice
[19], for this new study we investigated the mThy1-α-syn
(line 61), as well as crosses with the mThy1-APP mutant
Figure 11 Accumulation of CT α-syn and caspase-3 activation in α-syn/APP tg mice. A. Confocal images and B image analysis of increased
caspase-3 activation in the hippocampal CA3 region. While caspase-3 was significantly increased in all tg lines compared to non-tg mice, the most
dramatic increase was in the α-syn/APP tg mice. C. Photomicrographs and D image analysis of C-terminal α-syn accumulation of α-syn CT fragments.
Accumulation of CT-α-syn was significant in the α-syn tg line and was most significantly increased in the α-syn/APP tg line. E. Representative Western
blot and F. immunoblot analysis showing increased levels of α-syn CTF and mGluR5 in APP, SYN, and SYN/APP tg mice. * = p-value < 0.05,
and ** = p-value < 0.01 by one-way ANOVA and Dunnett’s post hoc analysis compared to non-tg mice. For each analysis, N = 6 (3–4 months old) mice
from each line were utilized.
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mutant tg line is new and has not been reported before.
These lines were selected to ensure expression of α-syn
and APP in the same neuronal populations and because
the high levels of expression in the hippocampus and the
extent of the α-syn and Aβ pathology [36,37]. Thus while
for the previous study we focused on the effects of α-syn
alone, for this study the emphasis was in investigating the
combined effects of α-syn and Aβ and the downstream
consequences on vulnerability and degeneration of hippo-
campal neurons. In the single and α-syn/APP tg mice neu-
rodegeneration was only observed in CA3 but not in CA1.
In contrast, injection of LV-mGluR5 resulted in degener-
ation of the CA1 region, while down-regulating
mGluR5 in tg mice and in neuronal cultures wasprotective from the toxic effects of α-syn and Aβ.
The mechanisms are not completely clear; however,
one possibility is that α-syn aggregates might interfere
with mGluR5 internalization via interactions with β-
arrestin, which is involved in mGluR5 re-cycling [19].
Higher levels of mGluR5 in selected neuronal popula-
tions might render them more sensitive to the effects of
excitatory agonists, such as glutamate and potentially Aβ.
The combined toxic effects of α-syn and Aβ via mGluR5
appeared to involve truncation of α-syn mediated by
calpain-I. Previous studies have shown that c-terminally
truncated α-syn is more prone to aggregate and to
lead to neurotoxicity [52-55]. Both in the brains of
patients with DLB/PD as well as in our α-syn tg mice
[51] and in BAC-α-syn rats [56], c-terminally truncated
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has been shown to play an important role [48]. The c-
terminally truncated fragment we detected was consistent
with calpain-I cleavage site as previously reported [51].
In our model, one possibility supported by the in vitro
studies is that Aβ/α-syn interacts with mGluR5 might
result in increased intracellular calcium that in turn
could activate calpain-I triggering α-syn truncation and
further aggregation. This is consistent with the known role
of mGluR5 hyper-excitation mediated by Aβ [42,57].
The role of mGluR5 in AD and PD has been the subject
of considerable interest because of the potential for a
therapeutic target [58]. It has been shown that in AD the
Aβ oligomers interact with mGluR5 [42,59] and that Aβ
dysregulates astroglial mGluR5 and calcium signaling [60].
In addition, inhibition of mGluR5 is neuroprotective
against Aβ toxicity [40] and mGluR5 is up regulated in
Down syndrome [31]. In PD and related models, modula-
tion of mGluR5 ameliorates the deficits in the MPTP
treated mice [61] and 6-OH DOPA model [62].
Previous studies support the notion that α-syn and Aβ
interact [63]. In Lewy body disease Aβ deposition is as-
sociated with α-syn lesions [9] and in crosses between
PDGF-APP mutant and PDGF-α-syn, the α-syn pathology
and related deficits are exacerbated [12]. Similar results
have been reported when crossing 3xTg-AD mice with
mPrP-α-syn A53T tg mice [15] and between PDGF-α-syn
and mThy1-APP mutant tg mice [13]. In addition, α-syn
mediated synapse damage is enhanced by Aβ [64] and α-
syn and Aβ cross-seed [13,14,65,66].
Conclusions
In order to understand the role of α-syn and Aβ in mediat-
ing neurodegeneration in the hippocampus via mGluR5,
we generated α-syn/APP double tg mice by crossing
mThy1-α-syn (Line 61) and mThy-1 APP (Line 41). In this
model full-length α-syn and mGluR5 were increased in the
CA3 pyramidal layer of the hippocampus in α-syn/APP
mice compared to α-syn tg mice. This was the same region
of the hippocampus that was selectively vulnerable in APP,
α-syn, and α-syn/APP tg mice. Lentivirus-mediated deliv-
ery of mGluR5 in vivo in the CA1 region, which was previ-
ously unaffected in the tg mice lines, led to increased
vulnerability. Down-regulating or pharmacologically block-
ing mGluR5 protected hippocampal neurons from the
neurotoxic effects of Aβ and α-syn. Further experiments
suggested that the vulnerability of hippocampal neurons to
α-syn and Aβ might be due to calcium influx mediated
through mGluR5 via calpain and caspase-3 activation
resulting in CT-truncation of α-syn. Together, these re-
sults support the possibility that vulnerability of hippo-
campal neurons to α-syn and Aβ might be mediated via
mGluR5. Moreover, therapeutical interventions targeting
mGluR5 might have a role in DLB.Material and methods
Generation of mThy-1 hAPP, hα-synuclein, and α-syn/APP
transgenic mice
The University of California at San Diego’s animal sub-
jects committee approved all experiments. Mice express-
ing human (h)α-syn-bearing under the neuronal mThy-1
promoter cassette (provided by Dr. H. van der Putten,
Ciba-Geigy, Basel, Switzerland) were generated as previ-
ously described [37]. Mice expressing hAPP751 cDNA
containing the London (V717I) and Swedish-(K670M/
N671L) mutations under the regulatory control of the
murine (m)Thy-1 gene (mThy1-hAPP751) were gener-
ated as previously described [36]. These single tg mice
were then cross-bred to generated mThy-1 α-syn/APP
double tg mice.Construction of lentiviral vectors
The mouse mGluR5 cDNA was cloned into the 3rd gen-
eration lentivirus vector by PCR addition of the ApaI
and BamHI restriction sites. This vector contains the hu-
man CMV promoter driving transgene expression and the
WPRE element for increased mRNA stability. The sh-
mGluR5 (GCA ACA TCC CGA ACA GTAA) was cloned
into the pSI-H1-copGFP vector (SBI Vector) containing
the H1 promoter. The control shRNA lentivector (LV-sh-
Luc) contains an shRNA directed against firefly luciferase.
Lentiviruses expressing -α-syn, mGluR5, sh-mGluR5, sh-
luciferase or empty vector (as controls) was prepared by
transient transfection in 293 T cells. The LV-α-syn has
previously been characterized [67]. Lentivirus vectors were
prepared by transient transfection of the 3 packaging plas-
mids and the vector plasmid in 293 T cells as previously
described [68,69].Mouse lines and intracerebral injections of lentiviral
vectors
A cohort of n = 48 (n = 24 LV-control and n = 24 LV-
mGluR5) mice were divided into the following groups:
a) non-tg, b) APP, c) α-syn and d) α-syn/APP tg mice
(6 month old, n = 6 with LV-control and n = 6 LV-
mGluR5 per group), were injected with 3 μL of the lenti-
viral preparations (2.5 × 107 TU) into the hippocampus
CA1 region (using a 5 μL Hamilton syringe). Similarly a
cohort of n = 48 were injected with LV-control (n = 24)
and LV-sh mGluR5 (n = 24). Briefly, as previously de-
scribed [70], mice were placed under anesthesia on a
Koft stereotaxic apparatus and coordinates (hippocam-
pus: AP 2.0 mm, lateral 1.5 mm, depth 1.3 mm) were de-
termined as per the Franklin and Paxinos atlas [71]. The
lentiviral vectors were delivered using a Hamilton syr-
inge connected to a hydraulic system to inject the solu-
tion at a rate of 1 μL every 2 min. To allow diffusion of
the solution into the brain tissue, the needle was left for
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Mice survived for 3 months after the lentiviral injection.
Tissue preparation
Following NIH guidelines for the humane treatment of
animals, mice were anesthetized with chloral hydrate
and flush-perfused transcardially with 0.9% saline. Brains
were removed and divided in sagittal sections. The right
hemi-brain was post-fixed in phosphate-buffered 4% PFA
(pH7.4) at 4°C for 48 h for neuropathological analysis,
while the left hemibrain was snap-frozen and stored at
−70°C for subsequent RNA and protein analysis.
RNA extraction and quantification of mRNA by real time-
PCR analysis
RNA was extracted from mice in triplicate using the
RNAeasy kit (QIAGEN, Germantown, MD, USA) [37],
and quantified by spectrophotometer readings. For
cDNA synthesis, 1 μg total RNA was reverse transcribed
using iScript cDNA Synthesis kit (BioRad, Hercules, CA,
USA). Real Time-PCR (RT-PCR) experiments were per-
formed using the iQ5 Detection System (BioRad, Hercules,
CA, USA). Amplification was performed on cDNA equiva-
lent to 25 ng total RNA with 1 × iQ SYBRGreen Supermix
(BioRad, Hercules, CA, USA). Template PCR reactions
were performed in triplicate and run in duplicate using the
following PCR cycling parameters: 50°C for 2 min, 95°C
for 10 min, and 40 cycles of 94°C for 15 s, 60°C for 1 min
followed by a dissociation protocol to verify the pres-
ence of a single product for each amplicon. The amount
of cDNA was calculated by the comparative threshold
cycle method and expressed using mouse actin as an in-
ternal control.
Immunohistochemical analysis
Analysis was performed using free-floating, 40 μm thick,
vibratome cut, blind-coded sections, as previously de-
scribed [51,72]. Briefly, sections were incubated over-
night at 4°C with antibodies against total α-syn (1:500,
affinity purified rabbit polyclonal, Millipore) [73], C-
terminus α-syn (SYN105, mouse monoclonal) [51], and
mGluR5 (1:500; Millipore), followed by biotin-tagged
anti-rabbit or anti-mouse IgG1 (1:100, Vector Laboratories,
Inc., Burlingame, CA) secondary antibodies, Avidin D-
HRP (1:200, ABC Elite, Vector), and visualized with
diaminobenzidine (DAB). Background levels were ob-
tained in tissue sections immunostained in the absence of
primary antibody. Therefore: corrected optical density =
optical density – background. Sections were scanned with
a digital Olympus bright field digital microscope (BX41).
Analysis of neurodegenerative pathology was per-
formed in vibratome sections immunolabeled with anti-
bodies against the dendritic marker microtubule-associated
protein-2 (MAP 2; 1:500, Millipore), pan-neuronal markerNeuN (1:500, Millipore), astroglial marker glial fibrillary
acidic protein (GFAP, 1:1000, Millipore) the microglial cell
marker Iba-1 (Wako Laboratories, mouse monoclonal),
activated caspase-3 (1:500; Cell Signaling) and synaptic
marker synaptophysin (SY38, 1:500, Millipore) [51,73].
Sections reacted with antibodies against NeuN (1:4,000;
Millipore), GFAP and Iba-1 were incubated with biotinyl-
ated secondary antibodies, Avidin D-HRP, and visualized
with DAB. Sections reacted with antibodies against MAP
2 and synaptophysin were visualized with FITC-tagged
secondary antibody or the Tyramide Signal Amplification™
Direct (Red) system (1:100, NEN Life Sciences, Boston,
MA), respectively, mounted under glass coverslips with
anti-fading media (Vector Laboratories), and imaged with
the laser scanning confocal microscope (LSCM) (MRC1024,
BioRad).
Image analysis and stereology
Sections immunostained with antibodies against α-syn,
mGluR5 and GFAP were analyzed with a digital Olym-
pus bright field digital microscope (BX41). For each case
a total of three sections (4 digital images per section at
400 ×magnification) were obtained from the CA1 and
CA3 region of the hippocampus and analyzed as previ-
ously described with the image J program (NIH) to ob-
tain optical density, levels were corrected to background.
Sections labeled with Iba-1, were analyzed utilizing the
Image-Pro Plus program (Media Cybernetics, Silver
Spring, MD) (10 digital images per section at 400 ×mag-
nification) and analyzed in order to estimate the average
number of immuno-labeled cells per unit area (mm2)
and the average intensity of the immunostaining (cor-
rected optical density).
The numbers of NeuN-immunoreactive neurons were
estimated utilizing unbiased stereological methods [74].
Hemisected brains were cut as serial sections and every
12th section containing the neocortex, hippocampus and
striatum was outlined using an Olympus BX51 micro-
scope running StereoInvestigator 8.21.1 software (Micro-
BrightField, Cochester, VT). Grid sizes for the hippo-
campal CA3 and CA1 pyramidal layers were: 150 × 150
and 300 × 300 μm, respectively and the counting frames
were 30 × 30 and 50 × 50 μm, respectively. Perikarya
within section approximately 480 μm apart were counted
only if the first recognizable profile came into focus within
the counting frame. A systematic sampling of the regions
of interests was made from a random starting point. Full
penetration of the section by the antibody was confirmed
by focusing throughout the entire Z-axis. The average co-
efficient of error for each region was 0.09. Sections were
analyzed using a 100 × 1.4 PlanApo oil-immersion object-
ive. The average mounted tissue thickness was 10.1 μm,
and a 5 μm high disector allowed for 2 μm top and bot-
tom guard-zones.
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2 and synaptophysin were serially imaged with the
LSCM (MRC1024, BioRad) and analyzed with the Image
J program (NIH), as previously described [75]. For each
mouse, a total of 3 sections were analyzed and for each
section, 4 fields in the CA1 and CA3 of the hippocam-
pus were examined. Results were expressed as percent
area of the neuropil occupied.
Double immunolabeling and fluorescence co-labeling
To determine the co-localization between α-syn and
APP, as well as mGluR5 and cleaved caspase-3, double-
labeling experiments were performed as previously [75].
Sections were immunolabeled with the following pairs of
antibodies: a) human α-syn (SYN211, mouse monoclo-
nal, Millipore) and APP (6E10, mouse monoclonal Cov-
ance), b) human α-syn (SYN211, mouse monoclonal,
Millipore) and mGluR5 (Millipore, rabbit polyclonal)
and c) cleaved caspase-3 (Cell Signaling, rabbit poly-
clonal) and C-terminal α-syn (SYN105 mouse monoclo-
nal). All sections were processed simultaneously, and
experiments were performed in triplicate. The FL and
CT α-syn was detected with the Tyramide Red (NEN
Life Sciences) whereas APP and mGluR5 were detected
with FITC-tagged antibodies (1:75, Vector, Burlingame,
CA). Sections were imaged with a Zeiss 63X1.4 objective
on an Axiovert 35 microscope (Zeiss) with an attached
MRC1024 laser scanning confocal microscope (LSCM)
system (BioRad) [75].
Immunoblot analysis in co-immunoprecipitation
The levels of α-syn, APP and mGluR5 in mouse brains,
as well as the levels of α-syn, mGluR5, brain spectrin
and CT-α-syn in neuronal cultures were analyzed using
lysate that were extracted and fractioned into soluble
and insoluble fractions by ultracentrifugation [75]. Pro-
tein (20 μg/lane) was loaded onto 4-12% SDS/PAGE gels
and blotted onto PVDF membranes, incubated with
specific antibodies, followed by HRP-tagged secondary
antibodies (1:5,000; Santa Cruz Biotechnology). Bands
were visualized by enhanced chemiluminescence (ECL,
PerkinElmer, Boston, MA) and analyzed with a quantita-
tive Versadoc XL imaging apparatus (BioRad). β-Actin
(1:3,000) was the loading control.
To detect interactions between α-syn and caspase-3 co-
immunoprecipitation was performed as previously described
[76] in neuronal cell lines infected with LV-α-syn and
treated with Aβ oligomers. Briefly, immunoprecipitation
assays were carried out essentially as previously described
[77]. The lysates were then centrifuged for 20 min at
12,000 rpm, and the protein concentrations were deter-
mined with a BCA protein assay kit. Three hundred μg of
each of the supernatants was incubated with 1 μg of the
antibody against α-syn, overnight at 4°C. Then theimmunocomplexes were adsorbed to protein A-Sepharose
4B or protein G-Sepharose (Amersham, Piscataway, NJ).
After extensive washing with immunoprecipitation buffer,
which contained 1% Trion X-100, samples were heated in
NuPAGE SDS sample buffer (Invitrogen) for five min and
subjected to gel electrophoresis on tris-tricine gels
followed by immunoblot analysis with an antibody against
caspase-3. The inverse immunoprecipitation with caspase-
3 and immunoblotting with α-syn was also performed.
Primary neuronal cultures treatments, lentiviral vectors
and analysis
Hippocampal neuron cultures were prepared from P1
mouse hippocampi. Briefly, mouse hippocampi were dis-
sected in HBSS dissecting media containing 4 mM
NaHCO3 (7.5%) and 10 mM HEPES buffer. Neurons
were then dissociated by enzymatic treatment with
0.25% trypsin in dissecting media for 15 min at 37°C,
and subsequent mechanical disruption. Neurons were
plated at medium density (45,000 cells/cm2) on poly-L-
lysine coated coverslips (12 mm in diameter) in MEM
plating media containing 1 mM sodium pyruvate, 0.6%
glucose, 10% horse serum, and 2 mM glutamine. Cul-
tures were placed in an incubator at 37°C under a hu-
midified atmosphere of 5% CO2 in air for 2 hrs. The
plating culture medium was then replaced and cultures
were maintained in B27 supplemented Neurobasal
media (Invitrogen) until 12 days in vitro (DIV). Primary
neuronal cultures were infected with LV-control or LV-
α-syn and with LV-sh-Luc or LV-mGluR5 after 48 hrs
were treated with Aβ oligomers as previously described
[76]. Natural Aβ was prepared according to Walsh et al.
[78] (kindly provided by Dr. Eddie Koo) by incubating
control CHO cells or CHO cells expressing APP V717F
mutation (also referred as 7PA2 cells) with B27 condi-
tioned media for 16 hrs. Total AΒ concentration was de-
termined as previously described [79]. Neurons were
treated with 80 pM of natural Aβ for 24 hrs. Hippocam-
pal neurons were plated on coverslips were rinsed briefly
in PBS and fixed with 4% paraformaldehyde (PFA) and
4% sucrose in PBS-MC (phosphate buffered saline
with 1 mM MgCl2 and 0.1 CaCl2) for 10 min at room
temperature. Neurons were then double immunola-
beled as described above with antibodies against MAP
2 (Millipore) and α-syn (SYN211, Millipore). α-Syn
was detected with the Tyramide Red (NEN Life Sciences)
whereas MAP 2 was detected with FITC-tagged anti-
bodies (1:75, Vector, Burlingame, CA). Coverslips were
imaged with a Zeiss 63 × 1.4 objective on an Axiovert 35
microscope (Zeiss) with an attached MRC1024 laser scan-
ning confocal microscope (LSCM) system (BioRad) [75]
and analyzed with Image J to determine neurite length
and levels of α-syn-ir (pixel intensity). The capacity of the
LV-sh-mGluR5 at down-regulating mGluR5 was verified
Overk et al. Molecular Neurodegeneration 2014, 9:18 Page 16 of 18
http://www.molecularneurodegeneration.com/content/9/1/18in coverslips by immunocytochemistry with an antibody
against mGluR5 detected with Tryramide Red and by
immunoblot as described above.
Neuronal cell lines treatments, lentiviral vectors and
analysis
The rat neuroblastoma cell line B103 was used for
in vitro experiments because this cell line display neur-
onal features and we have shown that pathological fea-
tures of synucleonopathies emerge when infected with
LV-α-syn [69]. B103 cells were plated at 3.5×104 cells/
well on coverslips. After 6 hours cells were infected with
LV-control, LV-α-syn (MOI = 50) and treated overnight
later with Aβ oligomers (1 nM). Cells were then fixed in
4% paraformaldehyde and analyzed by immunocyto-
chemistry for the expression of α-syn (Millipore), CT-α-
syn (SYN105), caspase-3 (cell signaling) and mGluR5
(rabbit polyclonal) as described above. Cell lysates were
divided by ultracentrifugation into soluble and insoluble
fractions and analyzed by immunoblot for mGluR5, CT
α-syn, α-syn and brain spectrin (Millipore) as described
above.
To determine the involvement of mGluR5 in cytotox-
icity, prior to the addition of Aβ oligomers, sets of cells in-
fected with LV-control and LV-α-syn were pre-treated for
6 hrs with the mGluR5 antagonists MPEP hydrochloride
(50 μM) (Tocris) and MTEP (50 μM) (Millipore) or the
mGluR5 agonist DHPG Dihydroxyphenylglycine (10 μM)
(Tocris) and analyzed for calcium levels and cytotoxicity.
Cytotoxicity was assessed using the lactate dehydrogenase
(LDH, CytoTox 96 assay, Promega) and MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
Roche) cell viability assays, as per manufacturer’s in-
structions, to measure levels of cell death. Assessment
of calcium influx was carried out as previously de-
scribed [13] using a modified protocol of the FLIPR 4
calcium assay (Molecular Devices, Sunnyvale, CA). Briefly,
B103 cells were infected with lentiviral constructs. Cells
were infected at a MOI of 30, and two days after infection,
cells were plated at a density of 30,000 cells/well on Costar
96 well-black plates with flat clear bottom (Corning). After
an additional 24 hrs of incubation, media was replaced
by 100 μL of HBSS buffer, and 100 μL of calcium dye
(FLUO-4 NW, Invitrogen) was added to each well. Cells
were kept in the incubator at 37°C for 30 mins, followed
by incubation in the dark at room temperature for an add-
itional 30 mins before measuring fluorescence with an ex-
citation/emission filter at 470-495/515-575 nm on a DTX
880 Multimode Detector (Beckman Coulter). As a positive
control of calcium influx, 0.6 μg of ionomycin (Sigma, St.
Louis, MO), was added to control wells.
Finally to ascertain the role of calpain-I and caspase-3
in neurotoxicity prior to the addition of Aβ oligomers,
were pre-treated for 6 hrs with the calpain-I inhibitorcalpastatin (50 nM) (Takeda) and the caspase-3 inhibitor
N-Acetyl-Glu-Ser-Met-Asp-al (1 μM) (Sigma) followed
by analysis of cytotoxicity by LDH as described above.
Statistical analysis
All analyses used GraphPad Prism (version 5.0). Differ-
ences among means were assessed by one-way ANOVA
with Dunnett’s post-hoc test when compared to non-tg
and by Tukey-Kramer when comparing tg groups.
Two-way ANOVA with repeated measures followed by a
Bonferroni multiple comparisons post-hoc test was used
for analyzing the interactions between groups and time.
The null hypothesis was rejected at the 0.05 level.
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